IL199094A0 - Compositions containing a progestagen and a testosterone for treating dry eye - Google Patents

Compositions containing a progestagen and a testosterone for treating dry eye

Info

Publication number
IL199094A0
IL199094A0 IL199094A IL19909409A IL199094A0 IL 199094 A0 IL199094 A0 IL 199094A0 IL 199094 A IL199094 A IL 199094A IL 19909409 A IL19909409 A IL 19909409A IL 199094 A0 IL199094 A0 IL 199094A0
Authority
IL
Israel
Prior art keywords
progestagen
testosterone
compositions containing
dry eye
treating dry
Prior art date
Application number
IL199094A
Other languages
English (en)
Original Assignee
Southern College Of Optometry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern College Of Optometry filed Critical Southern College Of Optometry
Publication of IL199094A0 publication Critical patent/IL199094A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Eyeglasses (AREA)
IL199094A 2006-12-05 2009-06-02 Compositions containing a progestagen and a testosterone for treating dry eye IL199094A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/634,347 US20080132475A1 (en) 2006-12-05 2006-12-05 Treatment for dry eye
PCT/US2007/086517 WO2008070728A2 (en) 2006-12-05 2007-12-05 Treatment for dry eye using testosterone and progestagen

Publications (1)

Publication Number Publication Date
IL199094A0 true IL199094A0 (en) 2010-03-28

Family

ID=39476533

Family Applications (1)

Application Number Title Priority Date Filing Date
IL199094A IL199094A0 (en) 2006-12-05 2009-06-02 Compositions containing a progestagen and a testosterone for treating dry eye

Country Status (12)

Country Link
US (3) US20080132475A1 (enExample)
EP (2) EP2124958A4 (enExample)
JP (2) JP2010511730A (enExample)
KR (2) KR20090104813A (enExample)
CN (2) CN101636164A (enExample)
AU (1) AU2009202711A1 (enExample)
BR (2) BRPI0720172A2 (enExample)
CA (2) CA2671698A1 (enExample)
EA (2) EA200900663A1 (enExample)
IL (1) IL199094A0 (enExample)
MX (2) MX2009005994A (enExample)
WO (2) WO2008070728A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5894364B2 (ja) * 2007-08-16 2016-03-30 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼および付属器組織の炎症を処置するための治療組成物
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
US20110144077A1 (en) * 2008-08-05 2011-06-16 Thomas Cotter Treatment of retinal degeneration
UA114705C2 (uk) * 2011-01-26 2017-07-25 Аллерган, Інк. Андрогенна композиція для лікування офтальмологічного захворювання
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX362185B (es) * 2012-07-27 2019-01-08 Glia Llc Composiciones y tratamiento para enfermedades y trastornos del ojo.
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
WO2014152385A2 (en) 2013-03-15 2014-09-25 Glia, Llc Cranial delivery of pharmaceuticals
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
ES2986830T3 (es) * 2014-10-20 2024-11-12 Oyster Point Pharma Inc Métodos de tratamiento de afecciones oculares
US20180071313A1 (en) * 2015-04-03 2018-03-15 Santen Pharmaceutical Co., Ltd. Dry eye therapeutic agent comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3509585B1 (en) 2016-09-07 2023-11-01 Glia, LLC Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
TW202131927A (zh) * 2019-11-13 2021-09-01 美商葛莉亞有限責任公司 睾固酮組合物
WO2023107796A1 (en) * 2021-12-11 2023-06-15 The Regents Of The University Of California Ophthalmic formulations for macular degeneration

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS59184135A (ja) * 1983-04-04 1984-10-19 Teijin Ltd グリセリンピログルタミン酸エステル類を含有する医薬品組成物
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
DE3514724A1 (de) * 1985-04-24 1986-10-30 Albin F. Dr. 4200 Oberhausen Jereb Salbe zur verbeugung und behandlung von augen- und hauterkrankungen
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) * 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
ES2139005T3 (es) * 1992-04-21 2000-02-01 Schepens Eye Res Inst Terapia ocular con androgeno en el sindrome de sjogren.
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
US5366739A (en) * 1992-08-06 1994-11-22 Deo Corporation Method of ophthalmic drug delivery
CA2142103C (en) * 1992-08-28 2003-07-08 Haim Aviv Submicron emulsions as ocular drug delivery vehicles
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
CA2261263C (en) * 1996-07-22 2008-10-07 The Victoria University Of Manchester Use of sex steroid function modulators to treat wounds and fibrotic disorders
ATE293960T1 (de) * 1997-02-28 2005-05-15 Minnesota Mining & Mfg Transdermale vorrichtung zur verabreichungvon von testosteron
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
FR2774587B1 (fr) * 1998-02-09 2000-03-10 Oreal Utilisation d'une microdispersion de cire dans une composition cosmetique ou dermatologique
US6348210B1 (en) * 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
CA2376797C (en) * 1999-06-11 2011-03-22 Watson Pharmaceuticals, Inc. Administration of non oral androgenic steroids to women
WO2001041806A1 (en) * 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US6630175B1 (en) * 2000-06-29 2003-10-07 Johnson & Johnson Consumer Companies, Inc. Method of reducing eye irritation
AU2002245104B2 (en) * 2000-12-11 2006-08-17 Testocreme, Llc Topical testosterone formulations and associated methods
US6659985B2 (en) * 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
WO2004045510A2 (en) * 2002-11-15 2004-06-03 Panaseca, Inc. Methods and compositions for alleviating dry eyes
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US7960350B2 (en) * 2003-10-24 2011-06-14 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
US20050202097A1 (en) * 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
JP2008530127A (ja) * 2005-02-09 2008-08-07 マクサイト， インコーポレイテッド 眼の処置のための処方物
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen

Also Published As

Publication number Publication date
EP2101785A2 (en) 2009-09-23
US20210008079A1 (en) 2021-01-14
BRPI0720172A2 (pt) 2014-01-07
EA200900662A1 (ru) 2009-12-30
EP2101785A4 (en) 2009-12-30
KR20090104814A (ko) 2009-10-06
WO2008070726A2 (en) 2008-06-12
CA2671769A1 (en) 2008-06-12
MX2009005993A (es) 2009-12-14
CN101636164A (zh) 2010-01-27
AU2009202711A1 (en) 2009-07-23
CN101636165A (zh) 2010-01-27
WO2008070726A3 (en) 2008-08-21
KR20090104813A (ko) 2009-10-06
CA2671698A1 (en) 2008-06-12
EP2124958A2 (en) 2009-12-02
EA200900663A1 (ru) 2009-12-30
JP2010511730A (ja) 2010-04-15
WO2008070728A2 (en) 2008-06-12
WO2008070728A3 (en) 2008-08-07
US20080132475A1 (en) 2008-06-05
EP2124958A4 (en) 2009-12-30
BRPI0719918A2 (pt) 2014-03-04
US20140113889A1 (en) 2014-04-24
JP2010511729A (ja) 2010-04-15
MX2009005994A (es) 2009-12-14

Similar Documents

Publication Publication Date Title
IL199094A0 (en) Compositions containing a progestagen and a testosterone for treating dry eye
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
EG25849A (en) Composition for treating textile
IL193014A0 (en) Methods and compositions for treating schizophrenia
EP2224924A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
IL209895A (en) Compounds for the prevention and / or treatment of β-amyloidoses
EP2120561A4 (en) COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
ZA200900140B (en) Methods and compositions for treating biofilms
IL198852A0 (en) Compositions and methods for treating a neoplasm
IL194202A0 (en) Treatment using citrulline
EP2078522A4 (en) COMPOSITION FOR THE TREATMENT OF ALLERGIES
IL198310A0 (en) Compositions and method for hair loss prevention
ZA200900243B (en) Methods and composition for treating a material
IL210097A0 (en) Compositions and methods for treating unfluenza
TWI367274B (en) Composition for fabric treatment
MY157996A (en) Desulfurizing coke-water salurry and process for preparation thereof
GB0614988D0 (en) Autoclaves
IL198484A0 (en) Carbamate compounds for use in treating depression
GB0718918D0 (en) Compositions and methods for treating skin conditions
EP2119436A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES
IL196638A0 (en) Methods and compositions for treating disease
PT1865051T (pt) Composições de branqueamento
EP2094279A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZA
EG25869A (en) Textile treatment composition